Welcome to our dedicated page for Biorestorative Therapies SEC filings (Ticker: BRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BRTX鈥檚 disclosures are packed with clinical jargon, trial data tables, and patent diagrams that can overwhelm even seasoned biotech investors. If you have ever searched, 鈥淏ioRestorative Therapies SEC filings explained simply鈥� or wondered how Phase II milestones affect cash burn, this page is built for you.
Our AI deciphers every filing the moment it hits EDGAR. Whether you need the BioRestorative Therapies quarterly earnings report 10-Q filing to gauge R&D spend, or want BioRestorative Therapies Form 4 insider transactions real-time alerts to monitor executive moves, Stock Titan delivers concise summaries, key-metric tables, and plain-English explanations. Stop scrolling through 300 pages of a 10-K鈥攐ur engine highlights trial timelines, dilution clauses, and risk factors in seconds.
Looking for specific insights?
- 10-K & 10-Q: Track how BRTX-100 enrollment costs flow through the income statement鈥攕ee the BioRestorative Therapies annual report 10-K simplified for historical context.
- 8-K: Get 鈥淏ioRestorative Therapies 8-K material events explained鈥� when FDA feedback, capital raises, or licensing deals occur.
- Form 4: Follow 鈥淏ioRestorative Therapies executive stock transactions Form 4鈥� to spot insider sentiment, with instant alerts on each filing.
- DEF 14A: Read the 鈥淏ioRestorative Therapies proxy statement executive compensation鈥� section to compare incentive structures against trial milestones.
Every document, from BioRestorative Therapies earnings report filing analysis to shelf registrations, is updated in real time and paired with expert commentary. Spend less time decoding disclosures and more time making informed decisions鈥�understanding BioRestorative Therapies SEC documents with AI starts here.
BioRestorative Therapies, Inc. is soliciting proxies for its 2025 Annual Meeting to be held September 18, 2025, where stockholders will vote on two Class II director nominees, an amendment to increase the 2021 Stock Incentive Plan authorized shares from 6,850,000 to 9,850,000, ratification of CBIZ CPAs P.C. as the independent auditor for fiscal 2025, and a non-binding advisory vote on executive compensation. Only stockholders of record as of July 31, 2025 may vote; there were 7,978,117 common shares and 1,398,158 Series B preferred shares outstanding on that date.
Executive pay highlights: CEO Lance Alstodt鈥檚 2024 total reported compensation was $1,314,583 (compensation actually paid $1,202,070). Pay-versus-performance figures show cumulative TSR on a $100 investment of $32.95 (2024) with net losses of $(8,979,381) in 2024, $(10,417,704) in 2023 and $(13,222,296) in 2022. The proxy discloses identified material weaknesses in internal control over financial reporting and the auditor transition from Marcum LLP to CBIZ CPAs following Marcum鈥檚 attest business acquisition.
FAQ
What is the current stock price of Biorestorative Therapies (BRTX)?
What is the market cap of Biorestorative Therapies (BRTX)?
